---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-080251"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:23:09.080370+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx enters $3.2M debt amendment with Hercules and Domicilium; Royalty obligations up to $53M

## Summary
- Tranche 2 Advance of $3.175M provided under Sixth Amendment to Hercules loan; Bridge Loan of $288k also made.
- Conversion options: Tranche 1A/1B debt can convert into equity if Qualified Financing ≥$7M occurs before April 2025.
- Royalty Agreement: 33% of first three Almirall milestones and 25% of subsequent milestones, capped at $53M, plus 0.75% of ELX-02 and 0.50% of ZKN-013 revenue.
- Amended Securities Purchase Agreement grants anti-dilution rights to SD MF for 15 months.
- Reporting covenant for FY2023 audited financials extended to November 29, 2024.

## SEC filing metadata
- accession: 0001104659-24-080251
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465924080251/0001104659-24-080251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465924080251/tm2419633d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-080251
- JSON: https://secwatch.observer/filing/0001104659-24-080251.json
- Plain text: https://secwatch.observer/filing/0001104659-24-080251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.